We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Compelling Reasons for Investors to Hold on to Centene Stock
Read MoreHide Full Article
Centene Corporation (CNC - Free Report) currently gains from improved premium and service revenues, numerous contract wins, an expanding Marketplace business and a sound financial position.
CNC’s Zacks Rank & Price Performance
Centene currently carries a Zacks Rank #3 (Hold).
The stock has gained 5.1% in the past month against the industry’s 8.3% decline. The Zacks Medical sector declined 6.1% while the S&P 500 composite decreased 1.4% in the same time frame.
Image Source: Zacks Investment Research
Centene’s Robust Growth Prospects
The Zacks Consensus Estimate for Centene’s 2025 earnings per share (EPS) is pegged at $7.02, indicating an improvement of 3.1% from the 2024 estimate. The consensus mark for 2025 revenues is $169 billion, implying 4.7% growth from the 2024 estimate.
CNC’s Decent Earnings Surprise History
CNC’s bottom line outpaced estimates in three of the trailing four quarters and missed the mark once, the average surprise being 7.13%.
Centene’s Key Business Tailwinds
Centene's revenue growth is fueled by a robust and expanding customer base within its Medicaid and Medicare businesses, which drive premium increases. This is significant since premiums are the primary revenue driver for health insurers. The strength of these businesses has led to numerous contract awards and renewals, further supporting membership growth. As of Sept. 30, 2024, total membership was 28.6 million, which improved 2.4% year over year.
Centene’s expertise in specialized services has enabled it to build and enhance relationships with both members and providers. This capability allows it to deliver improved care to individuals enrolled in government-sponsored programs. Additionally, an aging U.S. population continues to favor Medicare plans, ensuring sustained demand for Centene's offerings.
In the first nine months of 2024, Centene reported a 4.2% year-over-year increase in premium and service revenues. Management projects it to range between $154 billion and $156 billion for 2025. Notably, Centene secured Medicaid contracts from state authorities in Ohio, Michigan and New Hampshire in 2024. Its Commercial Marketplace business maintains a strong national footprint, serving 4.5 million members as of Sept. 30, 2024, which advanced 22.3% year over year.
The company actively leverages mergers and acquisitions to enhance its capabilities and broaden its presence across the United States. Concurrently, it divests underperforming businesses to concentrate on its core Managed Care operations. These divestitures often support initiatives such as share buybacks and debt reduction. A reduced debt burden leads to lower interest expenses, which declined 2.2% year over year in the first nine months of 2024.
Centene's financial health is underscored by its sound cash reserves and adequate cash-generating abilities. As of Sept. 30, 2024, cash and cash equivalents were $14.6 billion.
Doximity’s earnings surpassed estimates in each of the last four quarters, the average surprise being 22.12%. The Zacks Consensus Estimate for DOCS’ 2025 earnings indicates a rise of 10% from the 2024 estimate. The consensus mark for revenues implies an improvement of 10.1% from the 2024 estimate. The consensus mark for DOCS’ 2025 earnings has moved 10.6% north in the past 60 days.
The bottom line of Ensign Group beat estimates in each of the trailing four quarters, the average surprise being 1.34%. The Zacks Consensus Estimate for ENSG’s 2025 earnings indicates a rise of 10.7% from the 2024 estimate. The consensus mark for revenues implies an improvement of 11% from the 2024 estimate. The consensus mark for ENSG’s 2025 earnings has moved 0.2% north in the past 30 days.
DaVita’s earnings outpaced estimates in three of the trailing four quarters and missed the mark once, the average surprise being 10.59%. The Zacks Consensus Estimate for DVA’s 2025 earnings indicates a rise of 15.7% from the 2024 estimate. The consensus mark for revenues implies an improvement of 3.7% from the 2024 estimate. The consensus mark for DVA’s 2025 earnings has moved 0.6% north in the past 60 days.
Doximity stock has inched up 0.5% in the past month. However, shares of Ensign Group and DaVita have declined 9.9% and 5.4%, respectively, in the same time frame.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Compelling Reasons for Investors to Hold on to Centene Stock
Centene Corporation (CNC - Free Report) currently gains from improved premium and service revenues, numerous contract wins, an expanding Marketplace business and a sound financial position.
CNC’s Zacks Rank & Price Performance
Centene currently carries a Zacks Rank #3 (Hold).
The stock has gained 5.1% in the past month against the industry’s 8.3% decline. The Zacks Medical sector declined 6.1% while the S&P 500 composite decreased 1.4% in the same time frame.
Image Source: Zacks Investment Research
Centene’s Robust Growth Prospects
The Zacks Consensus Estimate for Centene’s 2025 earnings per share (EPS) is pegged at $7.02, indicating an improvement of 3.1% from the 2024 estimate. The consensus mark for 2025 revenues is $169 billion, implying 4.7% growth from the 2024 estimate.
CNC’s Decent Earnings Surprise History
CNC’s bottom line outpaced estimates in three of the trailing four quarters and missed the mark once, the average surprise being 7.13%.
Centene’s Key Business Tailwinds
Centene's revenue growth is fueled by a robust and expanding customer base within its Medicaid and Medicare businesses, which drive premium increases. This is significant since premiums are the primary revenue driver for health insurers. The strength of these businesses has led to numerous contract awards and renewals, further supporting membership growth. As of Sept. 30, 2024, total membership was 28.6 million, which improved 2.4% year over year.
Centene’s expertise in specialized services has enabled it to build and enhance relationships with both members and providers. This capability allows it to deliver improved care to individuals enrolled in government-sponsored programs. Additionally, an aging U.S. population continues to favor Medicare plans, ensuring sustained demand for Centene's offerings.
In the first nine months of 2024, Centene reported a 4.2% year-over-year increase in premium and service revenues. Management projects it to range between $154 billion and $156 billion for 2025. Notably, Centene secured Medicaid contracts from state authorities in Ohio, Michigan and New Hampshire in 2024. Its Commercial Marketplace business maintains a strong national footprint, serving 4.5 million members as of Sept. 30, 2024, which advanced 22.3% year over year.
The company actively leverages mergers and acquisitions to enhance its capabilities and broaden its presence across the United States. Concurrently, it divests underperforming businesses to concentrate on its core Managed Care operations. These divestitures often support initiatives such as share buybacks and debt reduction. A reduced debt burden leads to lower interest expenses, which declined 2.2% year over year in the first nine months of 2024.
Centene's financial health is underscored by its sound cash reserves and adequate cash-generating abilities. As of Sept. 30, 2024, cash and cash equivalents were $14.6 billion.
Stocks to Consider
Some better-ranked stocks in the Medical space are Doximity, Inc. (DOCS - Free Report) , The Ensign Group, Inc. (ENSG - Free Report) and DaVita Inc. (DVA - Free Report) . While Doximity currently sports a Zacks Rank #1 (Strong Buy), Ensign Group and DaVita carry a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Doximity’s earnings surpassed estimates in each of the last four quarters, the average surprise being 22.12%. The Zacks Consensus Estimate for DOCS’ 2025 earnings indicates a rise of 10% from the 2024 estimate. The consensus mark for revenues implies an improvement of 10.1% from the 2024 estimate. The consensus mark for DOCS’ 2025 earnings has moved 10.6% north in the past 60 days.
The bottom line of Ensign Group beat estimates in each of the trailing four quarters, the average surprise being 1.34%. The Zacks Consensus Estimate for ENSG’s 2025 earnings indicates a rise of 10.7% from the 2024 estimate. The consensus mark for revenues implies an improvement of 11% from the 2024 estimate. The consensus mark for ENSG’s 2025 earnings has moved 0.2% north in the past 30 days.
DaVita’s earnings outpaced estimates in three of the trailing four quarters and missed the mark once, the average surprise being 10.59%. The Zacks Consensus Estimate for DVA’s 2025 earnings indicates a rise of 15.7% from the 2024 estimate. The consensus mark for revenues implies an improvement of 3.7% from the 2024 estimate. The consensus mark for DVA’s 2025 earnings has moved 0.6% north in the past 60 days.
Doximity stock has inched up 0.5% in the past month. However, shares of Ensign Group and DaVita have declined 9.9% and 5.4%, respectively, in the same time frame.